GRAIL, Inc. Increase (Decrease) in Accounts Receivable
GRAIL, Inc. (GRAL) reported Increase (Decrease) in Accounts Receivable of $2.09 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06
- GRAIL, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$204.00K.
- GRAIL, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $2.30M.
- GRAIL, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $1.83M, a 64.18% decline year-over-year.
- GRAIL, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $75.00K, a 95.84% decline year-over-year.
- GRAIL, Inc. increase (decrease) in accounts receivable for fiscal 2025 was -$1.69M, a 150.00% decline from fiscal 2024.
- GRAIL, Inc. increase (decrease) in accounts receivable for fiscal 2024 was $3.37M, a 143.67% increase from fiscal 2023.
- GRAIL, Inc. increase (decrease) in accounts receivable for fiscal 2023 was $1.38M, a 84.06% decline from fiscal 2023.
- GRAIL, Inc. increase (decrease) in accounts receivable for fiscal 2023 was $8.68M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$204.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.09M 10-Q · filed 2026-08-06 | $3.92M derived: sum of 3 quarters · filed 2026-08-06 | $4.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.30M 10-Q · filed 2026-05-07 | $4.12M derived: sum of 2 quarters · filed 2026-05-07 | $4.20M derived: sum of 3 quarters · filed 2026-05-07 | $1.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.90M derived: sum of 2 quarters · filed 2026-03-12 | -$955.00K derived: sum of 3 quarters · filed 2026-08-06 | -$1.69M 10-K · filed 2026-03-12 |
| 2025-09-30 | $75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$2.78M derived: sum of 2 quarters · filed 2026-08-06 | -$3.51M 10-Q · filed 2025-11-13 | $1.59M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$2.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$3.59M 10-Q · filed 2026-08-06 | $1.51M derived: sum of 3 quarters · filed 2026-08-06 | $3.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$730.00K 10-Q · filed 2026-05-07 | $4.37M derived: sum of 2 quarters · filed 2026-05-07 | $6.18M derived: sum of 3 quarters · filed 2026-05-07 | $4.55M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $5.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $6.91M derived: sum of 2 quarters · filed 2026-03-12 | $5.28M derived: sum of 3 quarters · filed 2026-03-12 | $3.37M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $183.00K derived: sum of 2 quarters · filed 2025-11-13 | -$1.73M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | -$1.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$3.54M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | -$1.91M 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $1.38M 10-K · filed 2025-03-05 | |||
| 2023-01-01 | $8.68M 10-K · filed 2025-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |